EQL Pharma AB

EQL

SE0005497732

Drug Retailers

End-of-day quote NORDIC GROWTH MARKET Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
52.6 ^SEK	+5.20%		+11.44%	+57.49%

05-15	Transcript : EQL Pharma AB, Q4 2024 Earnings Call, May 15, 2024
05-14	EQL Pharma AB Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

EQL Pharma AB Elects Anders Månsson to Board of Directors

August 22, 2018 at 10:53 am

EQL Pharma AB (publ) announced that at its AGM held on August 22, 2018, elected Anders Månsson to Board of directors.

Latest news about EQL Pharma AB

Transcript : EQL Pharma AB, Q4 2024 Earnings Call, May 15, 2024	05-15
EQL Pharma AB Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-14	CI
EQL Pharma AB Reports Earnings Results for the Full Year Ended March 31, 2024	05-14	CI
Eql Pharma AB Provides Sales Guidance for the Year 2024/25	05-14	CI
EQL Pharma AB Announces Mellozzan Launched in Germany and Austria	04-22	CI
EQL Pharma AB Provides Sales Guidance for the Year 2023/24	02-13	CI
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-17	CI
EQL Pharma Plans 2024 Launch of Melatonin Product in Germany, Austria After Marketing Approvals	23-10-06	MT
EQL Pharma AB Announces its Mellozzan Gains Marketing Approval by Health Authorities in Germany and Austria	23-10-06	CI
EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-16	CI
Sweden’s EQL Pharma Launches ADHD Medicine in Denmark, Norway	23-08-15	MT
EQL Pharma AB Launches in Denmark and Norway by License Partner Medice Arzneimittel Pütter Gmbh & Co. Kg	23-08-15	CI
Fårö Capital Offloads 1 Million EQL Pharma Shares to Institutional Buyers	23-06-14	MT
EQL Pharma Out-Licenses Methenamine Hippurate to Dr. Pfleger Arzneimittel for the German Market	23-05-31	CI
EQL Pharma Enters into a Strategic Licensing Agreement with Adalvo for Mellozzan Outside of Europe	23-05-24	CI
EQL Pharma Licenses UTI Prevention Drug to French Women's Health Company	23-05-22	MT
EQL Pharma Out-Licenses Methenamine Hippurate to Laboratoires Majorelle for the French Market	23-05-22	CI
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer	23-05-17	MT
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.	23-05-16	CI
EQL Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-11	CI
Sweden's EQL Pharma Signs License Agreement for Melatonin Product in Turkey, Kazakhstan	23-04-28	MT
EQL Pharma AB Signs License Agreement with A Pharmaceutical Company in Turkiye for Mellozzan	23-04-28	CI
Sweden’s EQL Pharma Increases Bid for Sensidose	23-04-24	MT
EQL Pharma Launches SEK91 Million Takeover Bid for Sensidose	23-04-20	MT

EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Sector

Drug Retailers

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Sector Other Drug Retailers

	1st Jan change	Capi.
EQL PHARMA AB	+57.49%	145M
WALGREENS BOOTS ALLIANCE, INC.	-37.88%	13.99B
JD HEALTH INTERNATIONAL INC.	-33.12%	10.67B
YIFENG PHARMACY CHAIN CO., LTD.	+12.54%	6.29B
MATSUKIYOCOCOKARA & CO.	-11.17%	5.88B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+75.00%	4.93B
NAHDI MEDICAL COMPANY	-4.38%	4.54B
CLICKS GROUP LIMITED	-9.20%	3.74B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-19.40%	3.16B
WELCIA HOLDINGS CO., LTD.	-12.15%	2.85B

Other Drug Retailers

EQL Pharma AB

Equities

EQL

SE0005497732

Drug Retailers

EQL Pharma AB Elects Anders Månsson to Board of Directors

Latest news about EQL Pharma AB

Chart EQL Pharma AB

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Drug Retailers